172732-52-4Relevant articles and documents
Preparation method of o-nitrile phenylboronic acid-1, 3-propylene glycol ester
-
Paragraph 0036-0037, (2021/01/29)
The invention discloses a preparation method of o-nitrile phenylboronic acid-1, 3-propylene glycol ester, which belongs to the technical field of organic boric acid chemistry. The method comprises thefollowing steps of starting from o-bromobenzonitrile, carrying out a one-pot reaction with borate/n-butyllithium or metal lithium/boron halide amine, after the reaction is detected to be finished, carrying out acidolysis to obtain 2-nitrile phenylboronic acid, or directly filtering, distilling, adding 1, 3-propylene glycol to form ester, pulping, and purifying to obtain the o-nitrile phenylboronic acid-1, 3-propylene glycol ester. The key point of the process is that the reaction liquid is added into the acid water for quenching after the reaction is finished, so that the condition that the acid water is added into a reaction system to be subjected to an alkaline environment first and then to an acid environment is avoided, the yield is kept stable in different amplification stages, and the process has an industrial amplification prospect. And corresponding boric acid ester can be smoothly obtained by replacing propylene glycol with other glycols.
Organic electroluminescent materials and devices
-
Page/Page column 93, (2016/04/20)
Compounds comprising phosphorescent metal complexes comprising cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1′,2′-c]quinazoline ligands, or isoelectronic or benzannulated analogs thereof, are described. Organic light emitting diode devices comprising these compounds are also described.
METAL COMPLEXES OF CYCLOMETALLATED IMIDAZO[1,2-f]PHENANTHRIDINE AND DIIMIDAZO[1,2-A:1',2'-C]QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF
-
Paragraph 0258; 0259; 0260; 0261; 0262, (2016/10/07)
The present invention refers to-imidazo [1,2-f] the dee trillion which gets torn phenylphenanthridines and [1,2-a:1 ', 2' -c] quinazoline ligands, or its isoelectronic characteristic and or phosphor including analogue relates to compounds including metal complex. Furthermore, the present invention refers to these compounds including relates organic light emitting diode devices. (by machine translation)
METHOD OF PRODUCING 2-CYANOPHENYLBORONIC ACID DERIVATIVE
-
, (2017/11/14)
PROBLEM TO BE SOLVED: To provide a synthesis method for a 2-cyanophenylboronic acid derivative (2). SOLUTION: In the synthesis method, in the presence of alkali metal salt and lithium 2,2,6,6-tetramethylpiperidido, aromatic nitrile (1) and trialkoxyborane are reacted with each other. COPYRIGHT: (C)2015,JPOandINPIT
PROCESS FOR THE PREPARATION OF 2-CYANOPHENYLBORONIC ACID AND ESTERS THEREOF
-
, (2014/12/09)
The present invention relates to a process for the synthesis of 2-cyanophenylboronic acid and the esters and salts thereof of formula (II), which are intermediates of the synthesis of active pharmaceutical ingredients such as Perampanel or E2040. formula (II): (II).
Novel syntheses of fluorenones via nitrile-directed palladium-catalyzed C-H and dual C-H bond activation
Wan, Jung-Chih,Huang, Jun-Min,Jhan, Yu-Huei,Hsieh, Jen-Chieh
supporting information, p. 2742 - 2745 (2013/07/19)
Novel procedures for the [Pd]/[Ag]/TFA system catalyzed cascade reactions of nitrile directed remote C-H and dual C-H bond activation with insertion of nitrile were developed, which afforded variously polysubstituted fluorenones in moderate to good yields with tolerance of a wide variety of substrates.
Application of Ullmann and Ullmann-Finkelstein reactions for the synthesis of N-aryl-N-(1H-pyrazol-3-yl) acetamide or N-(1-aryl-1H-pyrazol-3-yl) acetamide derivatives and pharmacological evaluation
Deprez-Poulain, Rebecca,Cousaert, Nicolas,Toto, Patrick,Willand, Nicolas,Deprez, Benoit
experimental part, p. 3867 - 3876 (2011/11/12)
Ullmann-type reactions are becoming a major tool in medicinal chemistry. In this article, we describe the use of these Copper-catalyzed reactions with various precursors, acyl-heteroarylamines or pyrazoles of interest for pharmacomodulation. To the medicinal chemist they offer new, usually untapped disconnection approaches to compounds of interest. They thus open the way to new original analogues of bioactive compounds possibly not patented, from common building-blocks. They also allow C to N bioisosteric replacements, which sometimes are synthetically challenging. We report for the first time the critical effect of acetylamino substituents on the regioselective arylation of unsymmetrical pyrazoles that are useful for medicinal chemists. Finally, we have applied this strategy to the design of novel AT1 receptor antagonists. Though this family has been extensively investigated in the past 30 years, N-arylation and C to N replacement made possible by Ullmann chemistry, can produce original antagonists.
Phosphorescent condensed ring carbene metal complexes for use in organic light emitting devices
-
, (2010/11/04)
The invention relates to a compound comprising a phosphorescent metal complex comprising a monoanionic, bidentate ligand; wherein the metal is selected from the group consisting of the non-radioactive metals with atomic numbers greater than 40; and wherein the bidentate ligand comprises a carbene donor and may be linked with other ligands to comprise a tridentate, tetradentate, pentadentate or hexadentate ligand.
2-Cyanophenylboronic Acid or Ester Thereof in Which Impurities Are Decreased, and Production Method Thereof
-
Page/Page column 4, (2009/07/25)
A method for producing high-purity 2-cyanophenylboronic acid, characterized by reacting benzonitrile, lithium 2,2,6,6-tetramethylpiperidide, and trialkoxyborane, adding an aqueous acidic solution to a reaction solution containing the obtained 2-cyanophenylboronic acid, carrying out a contact treatment at a pH of below 7 in the presence of a water-immiscible organic solvent, and then obtaining the 2-cyanophenylboronic acid from the organic layer.
BIPHENYL DERIVATIVES
-
, (2008/06/13)
A biphenyl derivative represented by the following formula (I) or a pharmacologically acceptable salt thereof: STR1 wherein R 1, R. sup.2, R 3, R 4, and R 5 are defined in the specification, is clinically useful for treating and ameliorating mental disorders such as cerebrovascular disorder, aggressive behavior due to senile dementia, mental excitation, poriomania, delirium, hallucination, hyperkinesia, schizophrenia, emotional disturbance, depression, neurosis, psychophysiologic disorder and anxiety neurosis. The compounds exhibit dopamine 2 receptor antagonism and/or serotonin 2 receptor antagonism.